Patents by Inventor Yosef Shaul
Yosef Shaul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11873322Abstract: A recombinant system for improving genome editing via homologous recombination is disclosed. The system comprising a first nucleic acid sequence encoding a DNA editing agent having a double strand DNA cutting activity and a second nucleic acid sequence encoding a polypeptide capable of increasing homologous recombination in a target cell.Type: GrantFiled: June 25, 2019Date of Patent: January 16, 2024Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Nina Reuven
-
Publication number: 20230313173Abstract: Kits and methods for selecting a cell harboring a genome-editing event at a target sequence of interest are disclosed. One such kit comprises: (i) a first DNA editing agent for specifically introducing a mutation into a first gene so as to generate a first selection marker which imparts resistance to a selection agent, wherein the target sequence of interest the said first gene are distinct; and (ii) the selection agent; and/or (iii) a second DNA editing agent for specifically introducing a mutation into the first gene, wherein the mutation disrupts selection marker activity of the first selection marker.Type: ApplicationFiled: December 22, 2020Publication date: October 5, 2023Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef SHAUL, Nina REUVEN
-
Publication number: 20210115092Abstract: A recombinant system for improving genome editing via homologous recombination is disclosed. The system comprising a first nucleic acid sequence encoding a DNA editing agent having a double strand DNA cutting activity and a second nucleic acid sequence encoding a polypeptide capable of increasing homologous recombination in a target cell.Type: ApplicationFiled: June 25, 2019Publication date: April 22, 2021Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef SHAUL, Nina REUVEN
-
Patent number: 10155949Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: December 7, 2017Date of Patent: December 18, 2018Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20180087057Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: December 7, 2017Publication date: March 29, 2018Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Patent number: 9840711Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: February 27, 2017Date of Patent: December 12, 2017Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20170298361Abstract: Use of agents that down-regulates an amount and/or activity of Abelson murine leukemia viral oncogene homolog 1 (c-Abl) or checkpoint kinase 1 (Chk1) in the production of a medicament for treating obesity are disclosed.Type: ApplicationFiled: October 1, 2015Publication date: October 19, 2017Inventors: Yosef SHAUL, Rom David KESHET, Nina REUVEN
-
Publication number: 20170175127Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: February 27, 2017Publication date: June 22, 2017Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef SHAUL, Peter TSVETKOV, Julia ADLER
-
Patent number: 9579339Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: September 27, 2015Date of Patent: February 28, 2017Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20160008390Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: September 27, 2015Publication date: January 14, 2016Applicant: Yeda Research and Development Co. Ltd.Inventors: Yosef SHAUL, Peter Tsvetkov, Julia Adler
-
Patent number: 9145559Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: GrantFiled: October 25, 2012Date of Patent: September 29, 2015Assignee: Yeda Research and Development Co. Ltd.Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20140288157Abstract: A method of treating cancer is disclosed. The method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an agent which induces a dissociation of the 26S proteasomal complex into a 20S component and a 19S component to thereby inhibit 26S proteasomal activity, wherein the pharmaceutical agent is devoid of a chemotherapeutic agent.Type: ApplicationFiled: October 25, 2012Publication date: September 25, 2014Inventors: Yosef Shaul, Peter Tsvetkov, Julia Adler
-
Publication number: 20040138131Abstract: An isolated nucleic acid, a recombinant protein encoded thereby and uses thereof. The isolated nucleic acid including (a) a polynucleotide at least 60% identical to SEQ ID NOs:1, 3, 5 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty—50, gap extension penalty—3); (b) a polynucleotide encoding a polypeptide being at least 60% homologous with SEQ ID NO:4 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty—50, gap extension penalty—3); or (c) a polynucleotide hybridizable with SEQ ID NOs:1, 3, 5 or portions thereof at 68° C. in 6×SSC, 1% SDS, 5× Denharts, 10% dextran sulfate, 100 &mgr;g/ml salmon sperm DNA, and 32p labeled probe and wash at 68° C.Type: ApplicationFiled: January 20, 2004Publication date: July 15, 2004Inventors: Yosef Shaul, Romi Zemel
-
Publication number: 20030185857Abstract: An isolated nucleic acid, a recombinant protein encoded thereby and uses thereof. The isolated nucleic acid including (a) a polynucleotide at least 60% identical to SEQ ID NOs:1, 3, 5 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty—50, gap extension penalty—3); (b) a polynucleotide encoding a polypeptide being at least 60% homologous with SEQ ID NOs:2, 4, 6 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty—50, gap extension penalty—3); or (c) a polynucleotide hybridizable with SEQ ID NOs:1, 3, 5 or portions thereof at 68° C. in 6×SSC, 1% SDS, 5× Denharts, 10% dextran sulfate, 100 &mgr;g/ml salmon sperm DNA, and 32p labeled probe and wash at 68° C.Type: ApplicationFiled: May 23, 2003Publication date: October 2, 2003Applicant: Yeda Research And Development Co. Ltd.Inventors: Yosef Shaul, Romi Zemel
-
Publication number: 20030158251Abstract: A method of treating disorders associated with abnormal cell proliferation in a subject in need thereof is provided. The method is effected by administering to the subject a therapeutically effective amount of an agent capable of inhibiting NQO1 activity.Type: ApplicationFiled: January 29, 2002Publication date: August 21, 2003Inventors: Gad Asher, Joseph Lotem, Batya Cohen, Leo Sachs, Yosef Shaul
-
Patent number: 6589534Abstract: An isolated nucleic acid, a recombinant protein encoded thereby and uses thereof. The isolated nucleic acid including (a) a polynucleotide at least 60% identical to SEQ ID NOs:1, 3, 5 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty—50, gap extension penalty—3); (b) a polynucleotide encoding a polypeptide being at least 60 homologous with SEQ ID NOs:2, 4, 6 or portions thereof as determined using the Bestfit procedure of the DNA sequence analysis software package developed by the Genetic Computer Group (GCG) at the university of Wisconsin (gap creation penalty—50, gap extension penalty—3); or (c) a polynucleotide hybridizable with SEQ ID NOs:1, 3, 5 or portions thereof at 68° C. in 6×SSC, 1% SDS, 5×Denharts, 10% dextran sulfate, 100 &mgr;g/ml salmon sperm DNA, and 32p labeled probe and wash at 68° C.Type: GrantFiled: September 30, 1999Date of Patent: July 8, 2003Assignee: Yeda Research and Development Co., Ltd.Inventors: Yosef Shaul, Romi Zemel